These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


166 related items for PubMed ID: 30742590

  • 1. Effects of Cytochrome P450 2C19 Genetic Polymorphisms on Responses to Escitalopram and Levels of Brain-Derived Neurotrophic Factor in Patients With Panic Disorder.
    He Q, Mei Y, Liu Y, Yuan Z, Zhang J, Yan H, Shen L, Zhang Y.
    J Clin Psychopharmacol; 2019; 39(2):117-123. PubMed ID: 30742590
    [Abstract] [Full Text] [Related]

  • 2. Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder.
    He Q, Yuan Z, Liu Y, Zhang J, Yan H, Shen L, Luo X, Zhang Y.
    Pharmacogenet Genomics; 2017 Aug; 27(8):279-284. PubMed ID: 28614176
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.
    Bishop JR, Najjar F, Rubin LH, Guter SJ, Owley T, Mosconi MW, Jacob S, Cook EH.
    Pharmacogenet Genomics; 2015 Nov; 25(11):548-54. PubMed ID: 26313485
    [Abstract] [Full Text] [Related]

  • 5. Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder.
    Jarčušková D, Tkáč I, Hlaváčová N, Yaluri AS, Kozárová M, Habalová V, Klimčáková L, Židzik J, Javorský M, Bednářová A.
    BMC Psychiatry; 2024 Oct 15; 24(1):690. PubMed ID: 39407134
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.
    Chang M, Tybring G, Dahl ML, Lindh JD.
    Clin Pharmacokinet; 2014 Sep 15; 53(9):801-11. PubMed ID: 25154506
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study.
    Strawn JR, Mills JA, Schroeder H, Mossman SA, Varney ST, Ramsey LB, Poweleit EA, Desta Z, Cecil K, DelBello MP.
    J Clin Psychiatry; 2020 Aug 25; 81(5):. PubMed ID: 32857933
    [Abstract] [Full Text] [Related]

  • 10. Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression.
    Tsuchimine S, Ochi S, Tajiri M, Suzuki Y, Sugawara N, Inoue Y, Yasui-Furukori N.
    Ther Drug Monit; 2018 Jun 25; 40(3):356-361. PubMed ID: 29570504
    [Abstract] [Full Text] [Related]

  • 11. Influence of CYP2C19, CYP2D6, and ABCB1 Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study.
    Islam F, Magarbeh L, Elsheikh SSM, Kloiber S, Espinola CW, Bhat V, Frey BN, Milev R, Soares CN, Parikh SV, Placenza F, Hassel S, Taylor VH, Leri F, Blier P, Uher R, Farzan F, Lam RW, Turecki G, Foster JA, Rotzinger S, Kennedy SH, Müller DJ.
    Can J Psychiatry; 2024 Mar 25; 69(3):183-195. PubMed ID: 37796764
    [Abstract] [Full Text] [Related]

  • 12. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
    Huezo-Diaz P, Perroud N, Spencer EP, Smith R, Sim S, Virding S, Uher R, Gunasinghe C, Gray J, Campbell D, Hauser J, Maier W, Marusic A, Rietschel M, Perez J, Giovannini C, Mors O, Mendlewicz J, McGuffin P, Farmer AE, Ingelman-Sundberg M, Craig IW, Aitchison KJ.
    J Psychopharmacol; 2012 Mar 25; 26(3):398-407. PubMed ID: 21926427
    [Abstract] [Full Text] [Related]

  • 13. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.
    Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, Fang CK, Wu CS, Lu SC, Liu SC, Chen CY, Liu YL.
    Pharmacogenomics; 2010 Apr 25; 11(4):537-46. PubMed ID: 20350136
    [Abstract] [Full Text] [Related]

  • 14. Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.
    Rossow KM, Aka IT, Maxwell-Horn AC, Roden DM, Van Driest SL.
    Pediatrics; 2020 Dec 25; 146(6):. PubMed ID: 33234666
    [Abstract] [Full Text] [Related]

  • 15. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A.
    Encephale; 2008 Sep 25; 34(4):400-8. PubMed ID: 18922243
    [Abstract] [Full Text] [Related]

  • 16. The roles of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in predicting treatment remission in a Chinese Han population with generalized anxiety disorder.
    Shen Z, Zhu J, Yuan Y, Ren L, Qian M, Lin M, Cai M, Zhang Z, Shen X.
    Psychiatry Res; 2019 Jan 25; 271():319-324. PubMed ID: 30529313
    [Abstract] [Full Text] [Related]

  • 17. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.
    Yin OQ, Wing YK, Cheung Y, Wang ZJ, Lam SL, Chiu HF, Chow MS.
    J Clin Psychopharmacol; 2006 Aug 25; 26(4):367-72. PubMed ID: 16855453
    [Abstract] [Full Text] [Related]

  • 18. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
    Waade RB, Hermann M, Moe HL, Molden E.
    Eur J Clin Pharmacol; 2014 Aug 25; 70(8):933-40. PubMed ID: 24858822
    [Abstract] [Full Text] [Related]

  • 19. CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.
    Kumar Y, Kung S, Shinozaki G.
    J Psychopharmacol; 2014 Dec 25; 28(12):1143-8. PubMed ID: 25122046
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.
    Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, Zhou HH.
    Drug Metab Dispos; 2003 Oct 25; 31(10):1255-9. PubMed ID: 12975335
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.